Navigation Links
Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

ain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs; results of clinical trials or preclinical studies may not be predictive of future results; clinical trials and studies may not proceed at the time or in the manner Arena expects or at all; Arena's ability to partner or commercialize lorcaserin or other of its compounds or programs; the timing and ability of Arena to receive regulatory approval for its drug candidates; Arena's ability to obtain additional funds; Arena's ability to obtain and defend its patents; and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.


Contact: Arena Pharmaceuticals, Inc.
Jack Lief
President and CEO

Cindy McGee
Manager, IR and Corporate Communications
858.453.7200, ext. 1479

Media Contact: Russo Partners
David Schull, President
'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 ... ) has announced the addition of ... - Technologies, Markets and Companies"  to ... ,This report describes and evaluates animal ... medicine and pharmaceuticals as well as ...
(Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has announced ... "Cell Therapy - Technologies, Markets and Companies" ... and evaluates cell therapy technologies and methods, which ... in the practice of medicine. Hematopoietic stem cell ... transplants. Role of cells in drug discovery is ...
(Date:5/28/2015)... 28, 2015 Celsion Corporation (the "Company") (NASDAQ: ... commitments from two institutional healthcare investors to purchase an ... stock in an at-the-market registered direct offering and a ... The Company entered into a definitive purchase ... agreed to sell an aggregate of 3,000,000 shares of ...
(Date:5/28/2015)... Dallas, TX (PRWEB) May 28, 2015 ... trade association serving and representing the life sciences ... first Board of Directors meeting at The Foundry ... meeting of the organization brought together a broad ... region, and underscored the organization's early successes in ...
Breaking Biology Technology:Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 2Global Animal Biotechnology Report 2015 - Technologies, Markets and Companies Analysis to 2024 3Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3
... – Prodesse Inc. , a biotechnology company ... the testing of infectious diseases, has entered into an ... the Basel, Switzerland-based pharmaceutical firm. , ,Under the agreement, ... right to include Roche enzymes in its products. Prodesse ...
... of 2006 already. The first half stock market doesn't look pretty! ... Dow was up twice that level but took a tumble in ... July. The NASDAQ has really taken a hit in these first ... oil price increases, once again surpassing the $3/gallon level. This time, ...
... - During a conference call with investors, the new executive team ... signal from the NASDAQ Stock Market on its request for an ... ,Chairman Michael Dunham, joined by interim co-CEOs Brian Pedlar and Robert ... since the completion of a financial audit, but he made no ...
Cached Biology Technology:First half of 2006 roundup: Big Pharma trumps biotech 2First half of 2006 roundup: Big Pharma trumps biotech 3First half of 2006 roundup: Big Pharma trumps biotech 4First half of 2006 roundup: Big Pharma trumps biotech 5First half of 2006 roundup: Big Pharma trumps biotech 6No word on NASDAQ extension for Merge 2
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... April 14, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... the 2015 New York Design Awards under the category  ... York City Design Awards are part of a global ... 2,500 ratings from the marketplace, industry and judging panel. ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... taken a look at the year and chosen one ... as the most important in the stem cell category ... categories, including, as well as stem cells, immunology, cardiovascular ... by Manuel Serrano, the director of CNIO,s Molecular Oncology ...
... researchers will receive the 2013 EMBO Installation Grants. The ... up their research groups in the Czech Republic, Poland, ... to strengthen science in selected member states. "EMBO ... back to their home countries where they establish laboratories. ...
... Stelly and her father, Alabama cardiovascular surgeon Terry Stelly, ... surgery and found that the application allowed the human ... were published in the Annals of Thoracic Surgery ... naturally occurring substance that helps regulate cells and can ...
Cached Biology News:CNIO study chosen as discovery of the year in regenerative medicine 26 Installation Grants awarded 2
Request Info...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... Red System consists of concentrated X/R ... X/R Red Buffer. The X/R Red ... produce red staining that may be ... Buffer, 100 mL , Chromogen, 2.0 ...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Biology Products: